Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical ImplicationsGlobeNewsWire • 03/30/20
Is the Options Market Predicting a Spike in Axsome Therapeutics (AXSM) Stock?Zacks Investment Research • 03/23/20
Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease AgitationGlobeNewsWire • 03/20/20
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating OfficerGlobeNewsWire • 03/05/20
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of MigraineGlobeNewsWire • 02/20/20
Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should KnowZacks Investment Research • 01/28/20
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant DepressionGlobeNewsWire • 01/22/20